Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting
Poseida Therapeutics Inc., a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today presented preclinical data on P-PSMA-101, the company’s PSMA-specific chimeric antigen receptor T cell (CAR-T) stem cell memory drug candidate for the treatment of prostate cancer. P-PSMA-101 demonstrated potent anti-tumor efficacy, a persistently high percentage of the highly desirable stem cell memory T-cell subtype (Tscm) and no detectable tonic signaling or T-cell exhaustion. Additionally, researchers found that P-PSMA-101-modified T-cells persisted even after tumor elimination beyond detectable levels. The study was selected for oral presentation today at the American Association for Cancer Research Prostate Cancer: Advances in Basic, Translational, and Clinical Research meeting in Orlando, Florida.